Unknown PHASE4 INTERVENTIONAL NCT00199667

Concentration Controlled Versus Fixed Dose of MMF in Kidney Transplant Recipients

APOMYGRE : Multicenter, Randomized, Open-Label Study of MMF Therapeutic Follow-up's Interest in the the 12 First Months in Kidney Transplantation

Sponsor: Hoffmann-La Roche

Conditions Kidney Transplant Recipients

Interventions Mycophenolate Mofetil

Updated 5 times since 2017 Last updated: Dec 14, 2008 Started: Oct 31, 2002

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00199667, this PHASE4 trial focuses on Kidney Transplant Recipients and remains ongoing. Sponsored by Hoffmann-La Roche, it has been updated 5 times since 2002, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE4
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE4
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE4

First recorded

Oct 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hoffmann-La Roche
University Hospital, Limoges

Data source: University Hospital, Limoges

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amiens, France , Angers, France , Caen, France , Limoges, France , Paris, France , Poitiers, France , Reims, France , Rouen, France , Strasbourg, France , Toulouse, France and 1 more location